GlassScriptPhysician profile
Deepak H Singh
NPI 1023428851
$3,778.29
in general payments reported to CMS, 2019-2025
21 companies · $191 in 2025
The $191 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $368 · 2021: $529 · 2022: $761 · 2023: $1,056 · 2024: $608 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,854.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $750.19 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $539.07 | 2019-2025 | Dificid, Verquvo, Zerbaxa |
| Novartis Pharmaceuticals Corporation | $485.48 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $440.38 | 2019-2023 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $380.35 | 2021-2025 | Jardiance, Cyltezo, Spiriva Respimat |
| Shionogi INC | $329.59 | 2020-2024 | Fetroja |
| Pfizer INC. | $269.07 | 2019-2023 | |
| Abiomed | $217.76 | 2023-2025 | Impella |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.20 | 2023 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $53.28 | 2019-2021 | |
| Gilead Sciences, INC. | $28.47 | 2025 | |
| Kci USA, INC. | $26.28 | 2022 | |
| Verona Pharma, INC. | $26.00 | 2025 | Ohtuvayre |
| Sobi, INC | $24.67 | 2020 | |
| Exact Sciences Corporation | $24.25 | 2023 | Cologuard Collection Kit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.19 | 2025 | Lifevest |
| Medtronic Vascular, INC. | $19.90 | 2020 | |
| Paratek Pharmaceuticals, INC. | $19.26 | 2020 | |
| Abbvie INC. | $18.87 | 2022 | |
| Allergan, INC. | $17.81 | 2019 | |
| Ucb, INC. | $16.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.